NEXI Stock Overview
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
NexImmune, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.39 |
| 52 Week High | US$4.91 |
| 52 Week Low | US$0.19 |
| Beta | 0 |
| 1 Month Change | 75.79% |
| 3 Month Change | -46.24% |
| 1 Year Change | -86.92% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -98.47% |
Recent News & Updates
NexImmune (NASDAQ:NEXI) Will Have To Spend Its Cash Wisely
Sep 07
Neximmune GAAP EPS of -$0.69 misses by $0.01
Aug 15Shareholder Returns
| NEXI | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 7.5% | 1.6% | 3.1% |
| 1Y | -86.9% | 10.5% | -8.5% |
Return vs Industry: NEXI underperformed the US Biotechs industry which returned 8.3% over the past year.
Return vs Market: NEXI underperformed the US Market which returned -9.4% over the past year.
Price Volatility
| NEXI volatility | |
|---|---|
| NEXI Average Weekly Movement | 16.2% |
| Biotechs Industry Average Movement | 12.2% |
| Market Average Movement | 7.0% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: NEXI is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 16% a week.
Volatility Over Time: NEXI's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 74 | Kristi Jones | https://www.neximmune.com |
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company’s product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a candidate targeted against HPV-associated malignancies, which is in preclinical stage.
NexImmune, Inc. Fundamentals Summary
| NEXI fundamental statistics | |
|---|---|
| Market Cap | US$10.09m |
| Earnings (TTM) | -US$61.14m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.2x
P/E RatioIs NEXI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NEXI income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$61.14m |
| Earnings | -US$61.14m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.34 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did NEXI perform over the long term?
See historical performance and comparison